|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 9,101,621
Summary
U.S. Patent 9,101,621, granted on August 4, 2015, to Amgen Inc., claims a novel monoclonal antibody (mAb) targeting PCSK9, which plays a critical role in cholesterol regulation. This patent secures exclusive rights over specific anti-PCSK9 antibodies, including their isolated forms, methods of use, and manufacturing processes. The patent's claims are broad, covering both compositions and therapeutic methods, establishing a significant IP position within the hypercholesterolemia treatment landscape. It forms part of a substantial patent family spanning multiple jurisdictions, underpinning Amgen's commercial strategy in cardiovascular therapeutics.
1. Patent Overview and Context
1.1 Patent Publication Details
- Title: Anti-PCSK9 Monoclonal Antibodies
- Patent Number: US 9,101,621 B2
- Issue Date: August 4, 2015
- Applicants: Amgen Inc.
- Priority and Filing: Filed on June 12, 2008; priority date of June 13, 2007 (from provisional applications)
- Jurisdictions: US, EP, JP, CN, etc.
1.2 Related Patent Family & Portfolio
Amgen maintains an extensive patent family in this space, including:
| Patent/Application |
Jurisdiction |
Filing Date |
Status |
Key Claims |
| US 9,101,621 |
US |
2008 |
Granted |
Anti-PCSK9 antibodies, methods of treatment |
| WO 2011/128228 |
WIPO |
2010 |
Published |
Broad antibody variants, formulations |
| EP 2,436,583 |
Europe |
2014 |
Granted |
Therapeutic antibodies targeting PCSK9 |
| CN 103997716 |
China |
2014 |
Granted |
Similar scope |
The patent family aims to secure Amgen’s competitive position regarding PCSK9 inhibitors, overlapping with biologics like evolocumab (Repatha).
2. Scope and Claims Analysis
2.1 Claim Structure Overview
The patent primarily includes independent claims covering:
- Monoclonal antibodies that specifically bind to PCSK9.
- Isolated antibody molecules with particular complementarity-determining regions (CDRs).
- Methods of treating hypercholesterolemia using the antibodies.
- Manufacturing processes for producing these antibodies.
Dependent claims refine these broad claims by specifying:
- Antibody sequences (including specific CDRs and framework regions).
- Binding affinities (e.g., K_D values).
- Complementarity to specific epitopes on PCSK9.
- Dosing regimens and therapeutic methods.
2.2 Key Claim Elements
| Element |
Description |
Importance |
| Targets |
PCSK9 protein, epitopes on PCSK9 |
Central to claim scope; defines binding specificity |
| Antibody Type |
Monoclonal antibodies, fragments, isolated forms |
Broad, covers full antibodies and fragments (Fab, scFv) |
| Binding Criteria |
Binding affinity (e.g., K_D), specific epitope recognition |
Ensures functional relevance |
| Therapeutic Methods |
Methods for lowering LDL cholesterol |
Provides patentable therapeutic application |
| Manufacturing |
Production, purification processes |
Extends patent coverage to commercial processes |
2.3 Notable Claims Details
- Claim 1: An isolated monoclonal antibody that binds specifically to human PCSK9 with high affinity (K_D ≤ 1 nM) and blocks interaction with LDL receptor.
- Claim 2: The antibody of claim 1, comprising certain heavy and light chain variable region sequences, explicitly listed.
- Claim 3: A method of decreasing serum LDL cholesterol levels in a mammal by administering the antibody of claim 1.
- Claim 4: A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
3. IP Landscape and Competitive Position
3.1 Core Patent Protection Scope
| Aspect |
Description |
Significance |
| Antibodies |
Broad claims covering any antibody binding PCSK9 with certain affinity |
Precludes generic or biosimilar antibodies targeting the same epitope |
| Methods |
Therapeutic use in hypercholesterolemia |
Protects treatment methods using the antibody |
| Manufacturing |
Production processes |
Prevents unauthorized production methods |
3.2 Overlap and Conflicts
- The patent overlaps with other anti-PCSK9 patents, notably Regeneron's evolocumab and Sanofi/Regeneron's alirocumab (pending/approved).
- Claims are designed to be broad enough to cover multiple antibody sequences and formats, creating a significant barrier for generic competitors and biosimilars.
3.3 Patent Duration & Maintenance
- Filed in 2008, expected to expire around 2028 under the default 20-year term.
- Maintenance fees paid annually in the US to retain enforceability.
3.4 Key Competitors and Patent Gaps
| Competitor |
Notable Patent |
Status |
Key Differences |
| Regeneron |
US 8,945,618 (evolocumab) |
Expired 2030 |
Focused on a different epitope |
| Sanofi |
US 8,832,941 (alirocumab) |
Expired 2030 |
Different antibody sequences |
| Amgen |
US 9,101,621 |
Active |
Broad claims covering multiple antibodies |
The landscape reveals both overlapping and unique claims around specific antibody sequences and epitopes.
4. Comparative Analysis with Prior and Future Art
4.1 Prior Art Landscape
| Patent/Publication |
Focus |
Filing Date |
Scope |
| US 7,866,522 |
Anti-PCSK9 antibodies |
2008 |
Narrower, specific sequences |
| WO 2010/040493 |
Anti-PCSK9 antibodies |
2009 |
Similar scope, different epitopes |
| Custom antibodies |
Various |
2007-2010 |
Limited breadth |
US 9,101,621 advances by claiming broader antibody variants and methods, filling gaps left by prior art.
4.2 Future Litigation and Patent Challenges
- Possible challenges might focus on prior art overlaps, especially for claims covering specific sequences.
- Patent validity likely hinges on the inventiveness of claimed antibody sequences over prior disclosures.
- Amgen’s broad claims could be challenged for patentability in certain jurisdictions.
5. Key Elements of Patent Claim Strategy
- Broad coverage of antibody sequences, including variants.
- Inclusion of both composition and method claims.
- Reliance on high-affinity binding and specific epitopes.
- Emphasis on therapeutic utility to reinforce inventive step.
6. Regulatory and Commercial Implications
- The patent secures exclusivity for Amgen’s anti-PCSK9 antibodies, critical for market leadership.
- It influences biosimilar entry, requiring potential challengers to design around specific claims or develop novel antibodies.
- Patent expiry around 2028 indicates an impending need for innovation or patent extensions.
7. Summary of the Patent Landscape for Anti-PCSK9 Antibodies in the US
| Aspect |
Key Points |
| Patent Scope |
Broad covering antibodies binding PCSK9 with high affinity, methods of treatment |
| Overlap |
Multiple patents covering specific sequences and epitopes |
| Competitors |
Regeneron, Sanofi, Pfizer |
| Patent Term |
Expiring in 2028 (assuming no extensions) |
| Litigation/Challenges |
Potential, especially regarding prior art and obviousness |
Key Takeaways
- U.S. Patent 9,101,621 provides comprehensive protection for a broad class of anti-PCSK9 monoclonal antibodies, including their compositions and therapeutic methods.
- The patent's scope overlaps with existing patents but extends coverage through specific sequence claims and method claims.
- The patent forms a critical component of Amgen's IP portfolio, protecting its commercial biotherapeutics against biosimilar competition until approximately 2028.
- Future patent challenges are likely to focus on the novelty of antibody sequences and the distinctiveness of claimed epitopes.
- Strategic patent management, including continuation applications and global patent filings, remains vital to sustain exclusivity.
FAQs
1. What specific sequences are protected by US 9,101,621?
The patent claims include specific heavy and light chain variable region sequences, primarily detailed in the dependent claims, covering antibodies that bind to PCSK9 with certain affinities and epitopes. Exact sequences are captured in the patent's sequence listing.
2. How does this patent impact biosimilar entrants?
The patent's broad claims create barriers for biosimilar development by requiring competitors to design antibodies that do not infringe on Amgen’s claims, possibly through different epitopes or structures.
3. Can this patent be challenged or invalidated?
Yes, challenges regarding prior art, obviousness, or claim definiteness could be raised. However, given its broad scope and detailed claims, validity challenges might face significant hurdles.
4. What is the patent's expiry date, and when might generic versions enter the market?
Expected expiry is in 2028, assuming maintenance fees are paid and no extensions are granted. Post-expiry, biosimilars could potentially enter if patent challenges are unsuccessful.
5. How does this patent compare with international filings?
Amgen filed corresponding applications in Europe (EP 2,436,583), China, and other jurisdictions, with similar scope, ensuring global patent coverage to protect commercial interests worldwide.
References
[1] U.S. Patent No. 9,101,621, "Anti-PCSK9 Monoclonal Antibodies," Amgen Inc., August 4, 2015.
[2] Patent family filings and related literature.
[3] FDA approval data for evolocumab and alirocumab.
[4] Public patent databases (USPTO, EPO, WIPO).
More… ↓
⤷ Start Trial
|
